# Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression

> **NCT00285766** · PHASE3 · COMPLETED · sponsor: **Somerset Pharmaceuticals** · enrollment: 300 (—)

## Conditions studied

- Major Depression

## Interventions

- **DRUG:** Selegiline Transdermal System

## Key facts

- **NCT ID:** NCT00285766
- **Lead sponsor:** Somerset Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 300 (—)
- **Last updated:** 2008-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00285766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00285766, "Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00285766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*